The medical Director and interim co-Chief Medical Officer at Seattle Children's Therapeutics discussed possible research to move forward with CD19 T-APCs for patients with B-ALL.
“We're currently examining if it's worth taking T-APCs forward. I think these data are really promising. I think if we get to a point where we can find the right CAR T-cell products going forward, it would have to be a CD19 -targeting CAR product to bring forward CD19 T-APCs. So, we are looking at exploring that in future trials, to see if we could continue to study this and see if, in more patients, we do see that difference and longer-term remissions, longer term persistence of CAR T-cells.”
CD19t T-APCs (manufactured T cells with CD19 tag antigen presenting cells)have shown potential in enhancing cell persistence in patients with higher risk of relapse after treatment with SCRI-CAR19 for relapsed, refractory CD19+ B-cell acute lymphocytic leukemia (B-ALL).
Data from patients in the PLAT-02 (NCT02028455) and PLAT-03 (NCT03186118) trials were presented by Colleen E. Annesley, MD, Medical Director and interim co-Chief Medical Officer, Seattle Children's Therapeutics, and Associate Professor, Department of Pediatrics, University of Washington School of Medicine, in a poster at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California.
CGTLive spoke with Annesley to learn more about the PLAT-02 and PLAT-03 trials and continued research with T-APCs. She discussed challenges with manufacturing T-APCs, assessing the cell therapy in clinical trials, and improving access to these kinds of therapies.